Pernille Lassen1, Benjamin Lacas2, Jean-Pierre Pignon2, Andy Trotti3, Bjorn Zackrisson4, Qiang Zhang5, Jens Overgaard1, Pierre Blanchard6. 1. Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark. 2. Gustave-Roussy, Paris-Saclay University, Biostatistics and Epidemiology Department, Villejuif, France; INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif, France. 3. Moffitt Cancer Center, Department of Radiation Oncology, Tampa, USA. 4. Department of Radiation Sciences - Oncology, Umeå University, Umeå, Sweden. 5. NRG Oncology Statistics and Data Management Center (formerly RTOG), Philadelphia, USA. 6. Gustave-Roussy, Paris-Saclay University, Radiotherapy Department, Villejuif, France; INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif, France. Electronic address: pierre.blanchard@gustaveroussy.fr.
Abstract
BACKGROUND AND PURPOSE: Evaluate the prognostic and predictive impact of HPV-associated p16-expression and assess the combined prognostic impact of p16 and smoking on altered fractionated radiotherapy (AFRT) for oropharyngeal cancer (OPC) within the frames of the update of the Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH). MATERIALS AND METHODS: Patients with OPC, known tumor p16-status and smoking history were identified from the MARCH update, resulting in a dataset of 815 patients from four randomized trials (RTOG9003, DAHANCA6&7, RTOG0129, ARTSCAN). Analysis was performed using a Cox model stratified by trial and adjusted on gender, age, T-stage, N-stage, type of radiotherapy fractionation, p16, smoking. Primary endpoint was progression-free survival (PFS). RESULTS: In total, 465 patients (57%) had p16-positive tumors and 350 (43%) p16-negative. Compared to p16-negative, p16-positive patients had significantly better PFS (HR = 0.42 [95% CI: 0.34-0.51], 28.9% absolute increase at 10 years) and OS (HR = 0.40 [0.32-0.49], 32.1% absolute increase at 10 years). No interaction between p16-status and fractionation schedule was detected. Smoking negatively impacted outcome; in the p16-positive subgroup, never smokers had significantly better PFS than former/current smokers (HR = 0.49 [0.33-0.75], 24.2% survival benefit at 10 years). CONCLUSIONS: No predictive impact of p16-status on response to AFRT could be detected but the strong prognostic impact of p16-status was confirmed and especially p16-positive never smoking patients have superior outcome after RT.
BACKGROUND AND PURPOSE: Evaluate the prognostic and predictive impact of HPV-associated p16-expression and assess the combined prognostic impact of p16 and smoking on altered fractionated radiotherapy (AFRT) for oropharyngeal cancer (OPC) within the frames of the update of the Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH). MATERIALS AND METHODS:Patients with OPC, known tumorp16-status and smoking history were identified from the MARCH update, resulting in a dataset of 815 patients from four randomized trials (RTOG9003, DAHANCA6&7, RTOG0129, ARTSCAN). Analysis was performed using a Cox model stratified by trial and adjusted on gender, age, T-stage, N-stage, type of radiotherapy fractionation, p16, smoking. Primary endpoint was progression-free survival (PFS). RESULTS: In total, 465 patients (57%) had p16-positive tumors and 350 (43%) p16-negative. Compared to p16-negative, p16-positive patients had significantly better PFS (HR = 0.42 [95% CI: 0.34-0.51], 28.9% absolute increase at 10 years) and OS (HR = 0.40 [0.32-0.49], 32.1% absolute increase at 10 years). No interaction between p16-status and fractionation schedule was detected. Smoking negatively impacted outcome; in the p16-positive subgroup, never smokers had significantly better PFS than former/current smokers (HR = 0.49 [0.33-0.75], 24.2% survival benefit at 10 years). CONCLUSIONS: No predictive impact of p16-status on response to AFRT could be detected but the strong prognostic impact of p16-status was confirmed and especially p16-positive never smoking patients have superior outcome after RT.
Authors: Eva-Leonne Göttgens; Christian Ostheimer; Paul N Span; Jan Bussink; Ester M Hammond Journal: Br J Radiol Date: 2018-03-14 Impact factor: 3.039
Authors: Elgar Susanne Quabius; Alessa Heinrichs; André Kühnel; Martin Laudien; Florian Hoppe; Robert Mlynski; Petra Ambrosch; Markus Hoffmann Journal: Oncol Lett Date: 2022-03-28 Impact factor: 2.967
Authors: Moonef Alotaibi; Valeria Valova; Toni HÄnsel; Carmen Stromberger; Grzegorz Kofla; Heidi Olze; Iris Piwonski; Andreas Albers; Sebastian Ochsenreither; Annekatrin Coordes Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Zhigang Yuan; Arash O Naghavi; Dominic Tang; Youngchul Kim; Kamran A Ahmed; Jasreman Dhillon; Anna R Giuliano; Philippe E Spiess; Peter A Johnstone Journal: World J Urol Date: 2018-03-27 Impact factor: 4.226
Authors: Kristian Hastoft Jensen; Ivan Vogelius; Claus Ernst Moser; Elo Andersen; Jesper Grau Eriksen; Jørgen Johansen; Mohammad Farhadi; Maria Andersen; Jens Overgaard; Jeppe Friborg Journal: Br J Cancer Date: 2021-05-20 Impact factor: 7.640
Authors: Stephanie Y Chen; Aisling Last; Abhinav Ettyreddy; Dorina Kallogjeri; Benjamin Wahle; Smrithi Chidambaram; Angela Mazul; Wade Thorstad; Ryan S Jackson; Jose P Zevallos; Patrik Pipkorn Journal: Am J Otolaryngol Date: 2021-01-13 Impact factor: 1.808
Authors: Tom Bradish; H Fisher; V Paleri; M Robinson; D Meikle; C Kelly; J O'Hara Journal: Eur Arch Otorhinolaryngol Date: 2020-07-03 Impact factor: 2.503